SILOSilo Pharma, Inc.

Nasdaq silopharma.com


$ 1.76 $ 0.09 (5.26 %)    

Monday, 06-May-2024 15:57:35 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 1.8
$ 1.80
$ 0.00 x 0
$ 0.00 x 0
$ 1.76 - $ 1.80
$ 1.22 - $ 3.05
6,915
na
5.12M
$ -13.22
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-25-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-11-2023 06-30-2023 10-Q
4 05-12-2023 03-31-2023 10-Q
5 03-24-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-01-2022 06-30-2022 10-Q
8 05-13-2022 03-31-2022 10-Q
9 03-28-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-13-2021 06-30-2021 10-Q
12 05-17-2021 03-31-2021 10-Q
13 03-29-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-14-2020 06-30-2020 10-Q
16 05-12-2020 03-31-2020 10-Q
17 03-20-2020 12-31-2019 10-K
18 11-13-2019 09-30-2019 10-Q
19 08-13-2019 06-30-2019 10-Q
20 05-14-2019 03-31-2019 10-Q
21 04-04-2019 12-31-2018 10-K
22 11-14-2018 09-30-2018 10-Q
23 08-13-2018 06-30-2018 10-Q
24 05-15-2018 03-31-2018 10-Q
25 04-02-2018 12-31-2017 10-K
26 11-14-2017 09-30-2017 10-Q
27 08-14-2017 06-30-2017 10-Q
28 05-17-2017 03-31-2017 10-Q
29 03-31-2017 12-31-2016 10-K
30 10-28-2016 09-30-2016 10-Q
31 09-30-2016 06-30-2016 10-Q
32 08-31-2016 03-31-2016 10-Q
33 06-14-2016 12-31-2015 10-K
34 11-20-2015 09-30-2015 10-Q
35 08-14-2015 06-30-2015 10-Q
36 05-15-2015 03-31-2015 10-Q
37 03-31-2015 12-31-2014 10-K
38 11-14-2014 09-30-2014 10-Q
39 08-12-2014 06-30-2014 10-Q
40 05-02-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 silo-pharma-announces-results-for-intranasal-ptsd-treatment

Silo Pharma, Inc. (NASDAQ: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company foc...

 silo-pharma-set-to-acquire-exclusive-licensing-for-promising-alzheimers-disease-therapeutic-spc-14-shows-cognitive-and-stress-reduction-benefits-in-preclinical-models

SPC-14 shows cognitive and stress reduction benefits in preclinical models SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) --  Si...

 citizens-and-2-other-stocks-under-3-insiders-are-buying

The Dow Jones index closed lower by around 10 points on Monday. When insiders purchase or sell shares, it indicates their confi...

 silo-pharma-approved-extension-of-previously-announced-stock-repurchase-program-authorizing-purchase-of-up-to-1m-common-stock-until-april-30

- SEC Filing

 silo-pharma-and-3-other-stocks-under-5-insiders-are-buying

The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confid...

 silo-pharma-exercises-option-for-exclusive-license-agreement-for-first-in-class-ptsd-and-stress-induced-anxiety-therapeutic

Exclusive license for development, manufacturing, and commercialization in process

 silo-pharma-files-patent-for-groundbreaking-ketamine-implant-therapeutic-to-target-fibromyalgia-and-chronic-pain

Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focu...

Core News & Articles

https://www.marijuanamoment.net/indiana-lawmakers-send-psilocybin-research-funding-bill-to-governor/   The Indiana legislatur...

 silo-pharmas-provides-update-on-sp-26

Initial indications target fibromyalgia and chronic painLoaded and encapsulated drug maintains structural stability as implanta...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION